New industry evidence demands RWD disruption in pharma

Reuters Events, in partnership with Prognos Health, surveyed 215 brand, marketing, commercial strategy, medical affairs, and data science professionals in the pharmaceutical industry to understand current challenges and opportunities with real-world data (RWD) for therapy commercialization.

A Straighter Path to Underwriting

A straighter path to underwriting requires data to accurately predict risk, the visibility to identify high-cost prospects, and insights on the populations you want to insure.

Prognos Factor Explained

Analyzing de-identified patient data is essential to optimize commercial brand strategy. But current methods of obtaining this data can be challenging. See how you can accelerate your path to clinical truth with interoperable patient data and analytics software.
Text-Only Version